Abstract:The potential estrogenic activities of perfluoroalkyl substances (PFASs) are controversial. Here, we investigated the estrogenic/antiestrogenic activities of PFASs and explored the corresponding interaction mode of PFASs with the estrogen receptor (ER) by combining in vitro assays and in silico modeling. We found that three PFASs (perfluorobutanoic acid, perfluorobutane sulfonate, and perfluoropentanoic acid) exerted antiestrogenic effects by inhibiting luciferase activity, whereas perfluorohexane sulfonate (PFHxS) and perfluorooctane sulfonate (PFOS) exerted estrogenic effects by inducing luciferase activity. When coexposed to 17β-estradiol (E2), all tested PFASs attenuated the E2-stimulated luciferase activity; unexpectedly, each PFAS could further attenuate the luciferase activity generated by the cotreatment with ICI 182,780 and E2, with a minimal effective concentration comparable to that found in human serum. PFHxS and PFOS significantly induced the gene expression of TFF1; additionally, all PFASs inhibited the E2-induced gene expression of TFF1 and EGR3. Furthermore, the results of the blind docking analyses suggested that the interaction with the coactivator-binding region on the ER surface should be included as a pathway through which PFASs exert estrogenic and antiestrogenic activities. Finally, we revealed the critical molecular property of the zero-order molecular connectivity index (MCI) (0χ) that affects the antiestrogenic activity of PFASs.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.est.0c03468?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.est.0c03468</a>.Structures of tested chemicals (Table S1); concentrations of PFASs in exposure solutions (Table S2); binding free energy components of E2 and PFOS in the ER–E2–PFOS complex (Table S3); compounds, parameters, and activity data (Table S4); RNA isolation and reverse transcription polymerase chain reaction (RT-PCR) (part 1); in silico computational model (part 2); concentration–response luciferase activity of PFASs that gave a minor response in the MVLN assay (Figure S1); ERE-luciferase assay of PFASs in MVLN cells after cotreatment with E2 and ICI 182,780 (Figure S2); binding modes of 10 PFASs molecules in HIP molecular modeling (Figure S3); binding modes of 10 PFASs molecules in HIE molecular modeling (Figure S4); RMSD changes in MD simulations (Figure S5); and empirical distribution of R2* for the pEC50 model (Figure S6) (<a class="ext-link" href="/doi/suppl/10.1021/acs.est.0c03468/suppl_file/es0c03468_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Perfluorinated compounds binding to estrogen receptor of different species: a molecular dynamic modeling

Binding Specificities of Estrogen Receptor with Perfluorinated Compounds: A Cross Species Comparison.

The Endocrine Disrupting Effect of Perfluorooctanoic Acid (pfoa) on Human Estrogen, Androgen and Thyroid Receptors

Evaluation of the Estrogenic/Antiestrogenic Activities of Perfluoroalkyl Substances and Their Interactions with the Human Estrogen Receptor by Combining In Vitro Assays and In Silico Modeling

Structure-dependent binding and activation of perfluorinated compounds on human peroxisome proliferator-activated receptor γ

Analysis of Binding Modes between Three Perfluorosulfonates and GPER Based on Computational Simulation and Multiple Spectral Methods

Perfluorooctane sulfonate-induced testicular toxicity and differential testicular expression of estrogen receptor in male mice.

Tissue distribution of emerging per- and polyfluoroalkyl substances in wild fish species from Qiantang river, east China: Comparison of 6:2 Cl-PFESA with PFOS

Exploring toxicity of perfluorinated compounds through complex network and pathway modeling

Integration of in silico approaches to determination of endocrine-disrupting perfluorinated chemicals binding potency with steroidogenic acute regulatory protein

Perfluorinated Compound Exposure and Health Effects in Humans

Endocrine-disrupting activity of per- and polyfluoroalkyl substances: Exploring combined approaches of ligand and structure based modeling

Insight into the binding model of per- and polyfluoroalkyl substances to proteins and membranes

Protonation state effects of estrogen receptor α on the recognition mechanisms by perfluorooctanoic acid and perfluorooctane sulfonate: A computational study.

Per- and polyfluoroalkyl substances inhibit human and rat 17β-hydroxysteroid dehydrogenase 1: Quantitative structure-activity relationship and molecular docking analysis

Species-Specific Unbound Fraction Differences in Highly Bound PFAS: A Comparative Study across Human, Rat, and Mouse Plasma and Albumin

Probing the hepatotoxicity mechanisms of novel chlorinated polyfluoroalkyl sulfonates to zebrafish larvae: Implication of structural specificity

Toxic effects of perfluorinated compounds at human cellular level and on a model vertebrate

Poly- and perfluorinated compounds activate human pregnane X receptor

Toxic effects of three perfluorinated or polyfluorinated compounds (PFCs) on two strains of freshwater algae: Implications for ecological risk assessments

Binding of Pfos to Serum Albumin and Dna: Insight into the Molecular Toxicity of Perfluorochemicals